LONDON, June 8 (Reuters) - AstraZeneca Plc's key cholesterol drug Crestor has seen its market share growth in the United States stall, suggesting sales this year may struggle to meet forecasts, ...
Some cholesterol med-makers do have reason to rejoice today. AstraZeneca stopped a study of its blockbuster Crestor, saying the pill had already demonstrated clear benefits over placebo. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results